Exelixis 미래 성장

Future 기준 확인 2/6

Exelixis (는) 각각 연간 15.8% 및 9.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 17.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 18.7% 로 예상됩니다.

주요 정보

15.8%

수익 성장률

17.1%

EPS 성장률

Biotechs 수익 성장	27.6%
매출 성장률	9.1%
향후 자기자본 수익률	18.7%
애널리스트 커버리지	Good
마지막 업데이트	19 Dec 2024

최근 미래 성장 업데이트

Recent updates

Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine

Oct 31

Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Oct 31

If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

Jun 14

It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

May 24

Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

May 07

Exelixis: With Patent Litigation Decision Due Soon, There Are Options

May 02

Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Apr 22

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Mar 28

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Feb 26

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Jan 17

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Dec 27

수익 및 매출 성장 예측

NasdaqGS:EXEL - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	2,448	628	563	937	14
12/31/2025	2,195	494	493	668	20
12/31/2024	2,162	509	353	451	18
9/30/2024	2,082	467	405	470	N/A
6/30/2024	2,014	350	166	316	N/A
3/31/2024	1,847	205	185	318	N/A
12/31/2023	1,830	208	170	333	N/A
9/30/2023	1,774	92	134	396	N/A
6/30/2023	1,714	164	213	389	N/A
3/31/2023	1,664	154	118	299	N/A
12/31/2022	1,611	182	224	363	N/A
9/30/2022	1,638	308	343	385	N/A
6/30/2022	1,555	273	310	359	N/A
3/31/2022	1,521	298	453	509	N/A
12/31/2021	1,435	231	337	401	N/A
9/30/2021	1,254	164	275	338	N/A
6/30/2021	1,157	94	218	272	N/A
3/31/2021	1,031	65	152	192	N/A
12/31/2020	988	112	179	209	N/A
9/30/2020	958	152	310	334	N/A
6/30/2020	998	282	372	391	N/A
3/31/2020	979	294	408	421	N/A
12/31/2019	968	321	514	527	N/A
9/30/2019	956	612	465	474	N/A
6/30/2019	910	642	541	563	N/A
3/31/2019	856	650	473	506	N/A
12/31/2018	854	690	382	416	N/A
9/30/2018	745	368	316	364	N/A
6/30/2018	672	323	N/A	237	N/A
3/31/2018	585	253	N/A	169	N/A
12/31/2017	452	154	N/A	166	N/A
9/30/2017	410	150	N/A	197	N/A
6/30/2017	320	58	N/A	154	N/A
3/31/2017	257	6	N/A	122	N/A
12/31/2016	191	-70	N/A	210	N/A
9/30/2016	124	-147	N/A	90	N/A
6/30/2016	71	-181	N/A	61	N/A
3/31/2016	43	-186	N/A	60	N/A
12/31/2015	37	-162	N/A	-141	N/A
9/30/2015	35	-178	N/A	-156	N/A
6/30/2015	31	-195	N/A	-180	N/A
3/31/2015	30	-229	N/A	-208	N/A
12/31/2014	25	-261	N/A	-235	N/A
9/30/2014	22	-281	N/A	-233	N/A
6/30/2014	21	-286	N/A	-232	N/A
3/31/2014	27	-275	N/A	-216	N/A
12/31/2013	31	-245	N/A	-199	N/A

애널리스트 미래 성장 예측

수입 대 저축률: EXEL 의 연간 예상 수익 증가율( 15.8% )이 saving rate( 2.6% 보다 높습니다. ).

수익 vs 시장: EXEL 의 연간 수익( 15.8% ) US 시장( 15.2% 보다 빠르게 성장할 것으로 예상됩니다. 15.2% 연간).

고성장 수익: EXEL 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: EXEL 의 수익(연간 9.1% ) US 시장( 9.1% 보다 느리게 성장할 것으로 예상됩니다. 9.1% 연간).

고성장 수익: EXEL 의 수익(연간 9.1% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: EXEL 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 18.7 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/22 17:21
장 마감 주가	2024/12/20 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Exelixis, Inc. 39 애널리스트 중 20 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Ishan Majumdar	Baptista Research
Peter Lawson	Barclays
George Farmer	BMO Capital Markets Equity Research

Exelixis 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Price target increased by 7.1% to US$31.60

Consensus EPS estimates increase by 37%

Exelixis, Inc. Reaffirms Earnings Guidance for the Year 2024

Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024

Consensus EPS estimates fall by 10%

Consensus EPS estimates increase by 11%

Recent updates

Executive VP & General Counsel recently sold US$1.1m worth of stock

Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

Executive Vice President of Commercial recently sold US$667k worth of stock

Executive Vice President of Commercial notifies of intention to sell stock

Independent Director recently sold US$1.0m worth of stock

Investor sentiment improves as stock rises 20%

Independent Director notifies of intention to sell stock

Price target increased by 7.1% to US$31.60

Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine

Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Exelixis, Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2024

Here's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching

Exelixis, Inc. to Report Q3, 2024 Results on Oct 29, 2024

CEO, President & Director exercised options and sold US$479k worth of stock

Executive VP notifies of intention to sell stock

Exelixis, Inc Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine

Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult

Independent Director recently sold US$907k worth of stock

Consensus EPS estimates increase by 37%

Insider notifies of intention to sell stock

Exelixis Comes Up Aces

Exelixis, Inc. Announces Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $500 million worth of its shares.

Exelixis, Inc. Announces U.S. Food and Drug Administration Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors

Exelixis, Inc. to Report Q2, 2024 Results on Aug 06, 2024

If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

Independent Director recently sold US$576k worth of stock

It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

Independent Director notifies of intention to sell stock

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

Exelixis: With Patent Litigation Decision Due Soon, There Are Options

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Exelixis, Inc. Reaffirms Earnings Guidance for the Year 2024

Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Exelixis, Inc., Annual General Meeting, May 30, 2024

Exelixis, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Independent Director notifies of intention to sell stock

Executive Vice President of Commercial recently sold US$1.0m worth of stock

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Executive Vice President of Commercial notifies of intention to sell stock

Full year 2023 earnings: EPS exceeds analyst expectations

Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024

Exelixis, Inc. Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Executive VP notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Exelixis Announces Initiation of the Stellar-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer

Exelixis, Inc. Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.23 in 3Q 2022)

Consensus EPS estimates fall by 10%

Exelixis, Inc. Announces Detailed Results from Phase 3 Cabinet Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

Exelixis, Inc. to Report Q3, 2023 Results on Nov 01, 2023

CEO, President & Director exercised options and sold US$2.1m worth of stock

Exelixis, Inc. Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

Exelixis, Inc. Announces Vicki L. Goodman Concludes Her Service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

New major risk - Revenue and earnings growth

Executive Vice President of Commercial recently sold US$632k worth of stock

Consensus EPS estimates increase by 11%

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Executive VP notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations